NCT02428491View on ClinicalTrials.gov

Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth

PHASE3CompletedINTERVENTIONAL

Enrollment

354

Participants

Timeline

Start Date

April 20, 2015

Primary Completion Date

January 11, 2017

Study Completion Date

January 11, 2017

Conditions

DiphtheriaTetanusPertussisPoliomyelitisHepatitis BHaemophilus Influenzae Type b

Interventions

BIOLOGICAL

Hexaxim®

DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular

Trial Locations (1)

Unknown

Preventive Medicine Centre of Thai Binh Province, Thái Bình

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02428491 - Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth | Biotech Hunter | Biotech Hunter